Condition (MeSH)
Dissection, Thoracic Aorta
ClinicalTrials.gov lists 38 trials for Dissection, Thoracic Aorta or a narrower condition beneath it. W.L.Gore & Associates has the most among industry and government lead sponsors, with 4.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
30 of the 38 trials are tagged with Dissection, Thoracic Aorta itself; the rest are tagged with a narrower condition beneath it.
When did Dissection, Thoracic Aorta trials start? (18)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 6
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 3 |
| 2024 | 3 |
| 2023 | 6 |
| 2022 | 1 |
| 2021 | 2 |
| 2020 | 2 |
| 2019 | 3 |
| 2018 | 3 |
| 2016 | 1 |
Showing 10 of 18 earlier years.
No forecast is made for this condition: it averages 3.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 6 trials still running at the 2026-10-09 snapshot; registered median of 61 months across 15 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Dissection, Thoracic Aorta trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 2 |
| Phase 2/3 | 1 |
| Phase 3 | 1 |
| Phase 4 | 1 |
| Not applicable | 13 |
| Observational | 20 |
How many Dissection, Thoracic Aorta trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 11 |
| Enrolling by invitation | 2 |
| Active, not recruiting | 6 |
| Completed | 13 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Dissection, Thoracic Aorta trials? (7)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| W.L.Gore & Associates | 4 |
| Vascutek Ltd. | 3 |
| Lifetech Scientific (Shenzhen) Co., Ltd. | 2 |
| Medtronic Cardiovascular | 2 |
| Artivion Inc. | 1 |
Showing 5 of 7 sponsors.
Interventions as named in the registry (7)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Low dose losartan | 1 |
| Atenolol Pill | 1 |
| Thrombosomes | 1 |
| Recombinant Human Erythropoietin | 1 |
| Standard platelet concentrate | 1 |
Showing 5 of 7 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Dissection, Thoracic Aorta trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Endoleak | 107 | 1 |
| Vascular | 40 | 1 |
| Other | 24 | 1 |
| MI | 14 | 1 |
| Stroke | 14 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Dissection, Thoracic Aorta? (1)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| KLF15 maintains contractile phenotype of vascular smooth muscle cells and prevents thoracic aortic dissection by interacting with MRTFB. | The Journal of biological chemistry | 2024 | Yes |
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.